CervoMed’s Neflamapimod Added to U.K. ALS Platform

An update from CervoMed ( (CRVO) ) is now available.

CervoMed Inc., a U.S.-based clinical-stage biotechnology company listed on Nasdaq, develops oral small-molecule therapies for age-related neurodegenerative disorders, led by neflamapimod. The drug candidate targets p38 MAP kinase–mediated neuroinflammation and synaptic dysfunction, and has shown encouraging safety and efficacy signals in dementia with Lewy bodies and other brain disorders in early- and mid-stage trials.

On February 18, 2026, CervoMed announced that neflamapimod was selected for inclusion in the U.K. EXPERTS-ALS platform, a government- and charity-funded trial system designed to rapidly prioritize promising amyotrophic lateral sclerosis treatments. The NIHR-backed, Sheffield-sponsored trial will be the first to test neflamapimod in ALS, initially enrolling about 35 patients for 18–24 weeks with funding external to CervoMed, which could meaningfully expand the drug’s neurodegeneration footprint while the company continues to prioritize its planned Phase 3 dementia with Lewy bodies program.

Within EXPERTS-ALS, neflamapimod will be evaluated in a randomized, multicenter, open-label, multi-arm study using blood neurofilament light chain as the primary biomarker of neuroaxonal damage and disease activity. Positive data could justify expanding enrollment to as many as 80 patients and strengthen neflamapimod’s positioning as a potential disease-modifying therapy in ALS, offering upside for patients and investors if the biomarker and clinical readouts align with the drug’s prior translational and clinical results.

Academic experts cited neflamapimod’s ability to cross the blood–brain barrier, selectively inhibit p38, and its track record in dementia with Lewy bodies as key reasons for its inclusion in the platform. For CervoMed, participation in the fully funded U.K. platform provides a capital-efficient way to probe ALS while preserving resources for its core dementia program, potentially enhancing its strategic value in the competitive neurodegeneration drug-development landscape if the ALS data prove supportive.

The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

The score is held down primarily by weak financial performance—large and widening losses with accelerating cash burn and a shrinking equity base. Technicals also remain bearish with the stock below major moving averages and negative momentum. Offsetting these risks, recent FDA alignment and Phase 2b data provide positive clinical/regulatory catalysts, but valuation signals are limited due to negative earnings and no dividend.

To see Spark’s full report on CRVO stock, click here.

More about CervoMed

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. Its lead oral small-molecule candidate, neflamapimod, targets neuroinflammation and neurodegeneration, and is being advanced in indications including dementia with Lewy bodies, recovery after ischemic stroke, and primary progressive aphasia.

The company has reported positive Phase 2 data for neflamapimod in dementia with Lewy bodies, showing improvements in dementia severity, functional mobility, and key neurodegeneration biomarkers. CervoMed plans to initiate a global pivotal Phase 3 trial in dementia with Lewy bodies patients with low likelihood of Alzheimer’s co-pathology in the second half of 2026, subject to available funding.

CervoMed positions neflamapimod as a differentiated therapy by selectively inhibiting the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. More than 800 participants have been exposed to neflamapimod across Phase 1 and 2 studies, where the drug has generally been well tolerated and has shown consistent efficacy signals in neurodegenerative disease settings.

Average Trading Volume: 72,723

Technical Sentiment Signal: Strong Sell

Current Market Cap: $43.67M

See more insights into CRVO stock on TipRanks’ Stock Analysis page.